Bepridil
A calcium channel blocker that was used to treat chronic stable angina and certain heart arrhythmias. It works by slowing electrical conduction in the heart and relaxing blood vessels. Due to serious cardiac side effects, including potentially fatal arrhythmias, its use was discontinued in many countries.
Masse moléculaire
366,5000 g/mol
LogP
5,30
TPSA
15,70 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
Molecular Formula
C24H34N2O
HBD / HBA
- / 3
Liaisons Rotatives
10
Atomes Lourds
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A calcium channel blocker that was used to treat chronic stable angina and certain heart arrhythmias. It works by slowing electrical conduction in the heart and relaxing blood vessels. Due to serious cardiac side effects, including potentially fatal arrhythmias, its use was discontinued in many countries.
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Yes, Bepridil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1008. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2351. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bepridil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bepridil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bepridil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bepridil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bepridil"></drugfyi-drug>